Pfizer CEO likes U.K. for manufacturing but won't insure AstraZeneca jobs; Pozen gets CRL over plant issues;

> Drug developer Pozen said the FDA has sent it a complete response letter for its aspirin and omeprazole drug candidate because of manufacturing problems found at its API supplier. Release

> New Jersey based Pernix Therapeutics has completed the sale of its Houston manufacturing plant to Woodfield Pharmaceutical, netting $1.2 million on the deal. Release

> Capsugel will expand its Dosage Form Solutions (DFS) business to provide product for a drug being developed by New York-based Chiasma in partnership with Roche ($RHHBY). Release

> Roche ($RHHBY) has extended its contract with Indianapolis-based YourEncore, which will provide services to support enhancing productivity and strengthening regulatory compliance. Release

> A developer has been talking for four years about building a plant in Vermont for stem cell company AnC Bio and is now discussing this next step: a land-use permit. Story

> The Andhra Pradesh High Court has put a hold on the $3.2 billion sale of Ranbaxy Laboratories to Sun Pharmaceutical while it investigates the possibility of insider trading in India tied to the announcement. Story

And Finally... Pfizer ($PFE) CEO Ian Read said that tax incentives make the U.K. a good place for drug manufacturing but said he couldn't promise to keep all manufacturing jobs there if Pfizer is successful with its $100 billion buyout of AstraZeneca ($AZN). Story